Caricamento...
Ravulizumab: A Review in Atypical Haemolytic Uraemic Syndrome
Ravulizumab (Ultomiris(®)), a humanized monoclonal antibody that inhibits complement protein C5, is indicated for the treatment of atypical haemolytic uraemic syndrome (aHUS) in several countries, including the USA and those of the EU. Ravulizumab has been re-engineered from eculizumab to extend its...
Salvato in:
| Pubblicato in: | Drugs |
|---|---|
| Autore principale: | |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Springer International Publishing
2021
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8052220/ https://ncbi.nlm.nih.gov/pubmed/33738756 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40265-021-01481-6 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|